SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token $HMMM is gaining attention, with many users discussing its potential and availability on Phantom Wallet. Community members are using terms like "rocket," "moon," and "gem" to describe the token's momentum. Some users are also speculating about the driving forces behind the recent price action.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending due to its recent listing and small circulating supply, leading to volatile price action and community speculation about potential for rapid gains. Some users are reporting issues with trading on Coinbase, while others point to AI tools and broader market trends as potential catalysts. The token's limited supply of one million is a key talking point, with many anticipating significant price movement if it gains further attention.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as traders discuss its low market cap and circulating supply, anticipating a potential breakout. Some community members point to its integration with Aleph Zero, while others speculate about possible listings on major exchanges like Binance as a catalyst for significant gains. Technical analysis chatter includes mentions of oversold RSI conditions and bull flag formations.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the community debates its future following FDA approval of Tonmya, with discussions focused on potential sales, upcoming catalysts, and whether the stock is undervalued. Some traders express frustration with management and the stock's performance, while others remain optimistic about long-term growth and potential short squeezes. BlackRock's increased stake is being viewed as a potential bullish signal amid the ongoing volatility.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction as a community-driven token with viral hype, trending on Stocktwits with serious volume. The community emphasizes its strength and unity, rallying behind upcoming events like Karolina Arm's sponsored fight. Discussions highlight $SLAP's ambition to become a global brand, transcending its meme origins through real-world partnerships and a dedicated community.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

Columbus Circle Capital ($BRR) is trending as the community discusses Eric Jackson joining the board and anticipates a potential pump, drawing comparisons to past option surges. Chatter revolves around upcoming call options and a proposed merger with ProCap BTC, with some seeing a potentially favorable risk-reward scenario due to the SPAC's NAV floor. Recent news includes updates to the merger agreement and the appointment of a new CFO.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending amid discussions about its role in bridging blockchain technology with gaming, offering players ownership of digital assets and powering tokenized economies. Community members are actively discussing its potential in the expanding play-to-earn and virtual world sectors, as well as new exchange listings. Some traders are pointing out that the altcoin is closely related to Base, a layer-2 network that is built on top of the Ethereum blockchain.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to news of a potential shakeup in the Alzheimer's space following a recent investment in Vanqua Bio, which has investors speculating about Biogen's strategy around C5aR1 inhibitors, a target also being pursued by InflaRx ($IFRX). The community is analyzing the implications of Biogen's move for InflaRx's valuation and potential acquisition, viewing it as both mechanistic validation and a catalyst for sentiment. There is also discussion around Biogen's earnings and growth prospects, especially concerning new therapies offsetting multiple sclerosis portfolio weakness.

KraneShares Trust - KraneShares Global Humanoid and Embodied Intelligence Index ETF

KraneShares Global Humanoid and Embodied Intelligence Index ETF

$KOID is trending as discussions emerge around robotics and AI, specifically humanoid robots. Community members are actively comparing $KOID to other robotics ETFs and discussing the potential impact of Chinese investment in the sector, with some noting the fund's growing exposure and potential for long-term growth. Mentions of Elon Musk's views on robotics and humanoid development are also contributing to the conversation.

Tidal Trust II - YieldMax NVDA Option Income Strategy ETF

YieldMax NVDA Option Income Strategy ETF

NVDY is trending as investors discuss its dividend payouts and overall performance relative to its underlying asset, NVDA. The community is debating whether the ETF's returns justify its risks, especially given recent fluctuations in dividend yields and NAV. Some traders express disappointment with payout amounts, while others remain optimistic about its income-generating potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders. If you...

Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported that its oral drug Simufilam did not yield positive results in patients with mild to moderate Alzheimer’s disease in its second Phase 3 study.The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said.Cassava added that it would discontinue the Alzheimer’s disease development program with Simufilam by the end of the second quarter of 2025. &nbsp;REFOCUS-ALZ was discontinued on Nov. 25 last year after the company identified that a previous phase 3 study failed to yield positive results.Cassava CEO Rick Barry acknowledged the results were "unambiguous" and added that the company was “disappointed.”“Cassava will discontinue all efforts to develop Simufilam for Alzheimer’s disease, and we expect to phase out the program by the end of Q2 2025,” he said.The CEO added that the company has initiated preclinical studies to gauge the potential of Simufilam in treating TSC-related epilepsy.Company CFO Eric Schoen said the firm continues to be committed to enhancing shareholder value. “Cassava is well-capitalized with approximately $128.6 million in cash and cash equivalents as of Dec. 31, 2024,” he added.Cassava reported a net loss of $27.60 million in the three months ended December 2024 compared to a net loss of $20.92 million in the corresponding quarter of 2023.On Stocktwits, retail sentiment about Cassava Sciences climbed further into the ‘bullish’ territory (60/100), while message volume jumped from ‘normal’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:650/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_25_at_1_50_58_PM_png_d88af5aac9.webp" alt="SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits" width="650" height="146"><figcaption>SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expects the share price to drop further in the coming days.<stembedurl>https://stocktwits.com/pg3015/message/609181500</stembedurl>Another user expressed optimism, highlighting the company’s debt-free status.<stembedurl>https://stocktwits.com/mcrotary/message/609180826</stembedurl>SAVA stock has lost over 30% this year and is down by over 90% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/merck-enters-license-agreement-with-china-based-hengrui-pharma/ch7yxJsRbdw">Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful

The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025. 

Equity

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc...

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA Cassava Sciences, Inc. Securities Fraud Class...

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm Lead Plaintiff Deadline on February 10, 2025...

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff...

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to...

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA Cassava Sciences, Inc. Sued for Securities Law Violations...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.27	--	--	N/A
Q2 '25	--	-$0.92	--	N/A
Q1 '25	--	-$0.48	--	N/A
Q4 '24	-$0.58	-$0.57	2.29%	BEAT
Q3 '24	-$0.73	-$0.58	20.55%	BEAT

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest SAVA News

SAVACassava Sciences Inc